Delhi High Court Unleashes Generic Ozempic: Dr Reddy's Gets Export Green Light!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAbhay Singh|Published at:
Delhi High Court Unleashes Generic Ozempic: Dr Reddy's Gets Export Green Light!
Overview

In a significant win, the Delhi High Court has permitted Dr Reddy's Laboratories to manufacture and export its generic semaglutide, the key ingredient in Novo Nordisk's highly popular Ozempic and Wegovy weight-loss drugs. This ruling allows Dr Reddy's to sell in markets where Novo Nordisk lacks patent coverage, opening significant avenues for India's generic pharmaceutical sector in the high-growth anti-obesity market.

Delhi High Court Permits Dr Reddy's Export of Generic Semaglutide

Dr Reddy's Laboratories has secured a significant legal victory in the Delhi High Court, which has permitted the Indian drugmaker to manufacture and export its generic version of semaglutide. This key compound is behind Novo Nordisk's highly successful weight-loss medications, Ozempic and Wegovy. The court's decision allows Dr Reddy's to tap into international markets where Novo Nordisk's patents are not actively protected, marking a crucial step for India's generic pharmaceutical industry.

Court Ruling Details

  • A single-judge bench of Justice Manmeet Singh Arora delivered the verdict on Tuesday, allowing Dr Reddy's to proceed with domestic manufacturing and export of generic semaglutide.
  • The court found prima facie merit in Dr Reddy's challenge against the validity of Novo Nordisk's patent for semaglutide.
  • Dr Reddy's is permitted to export to countries where Novo Nordisk does not hold patent protection.
  • However, Dr Reddy's remains barred from selling the drug in India until March 2026, when Novo Nordisk's formulation patent expires locally.
  • This ruling comes after a series of legal proceedings, including a previous order in May that barred Dr Reddy's from selling within India but allowed manufacturing and export.

Patent Dispute Background

  • The dispute centres on semaglutide, originally developed by Novo Nordisk for type-2 diabetes and later approved for obesity treatment.
  • Novo Nordisk's primary composition patent for semaglutide expired in September 2024.
  • However, Novo Nordisk holds a subsequent formulation patent, valid until March 2026, which covers delivery mechanisms designed to enhance the drug's stability.
  • Dr Reddy's challenged this second patent, arguing it constitutes "evergreening" – an attempt to illegally extend monopoly protection beyond the primary patent's expiry.
  • Dr Reddy's asserts its right to export under India's Bolar exemption (Section 107A of the Patents Act), which allows manufacturers to produce patented drugs for export to countries where patents have expired or are not in force.
  • Novo Nordisk contests this, citing Section 48 of the Patents Act, which grants patent holders exclusive rights over making, using, and exporting their inventions, arguing that export cannot circumvent an active patent.

Market Implications

  • This ruling is poised to have significant ramifications for India's generic drug manufacturers, who are eager to enter the rapidly expanding global anti-obesity drug market.
  • The anti-obesity drug market in India has seen substantial growth, projected to increase from ₹133 crore in March 2021 to ₹576 crore by March 2025. Semaglutide currently holds a substantial share of this market.
  • Upon patent expiry, multiple Indian companies, including Sun Pharma, Mankind Pharma, and Natco Pharma, have indicated plans to launch more affordable generic versions of semaglutide.
  • The entry of generics is expected to increase competition and potentially lower drug prices, making treatments more accessible.

Other Players and Strategies

  • Natco Pharma has also filed a non-infringement suit, asserting that its semaglutide version does not violate Novo Nordisk's patents and should be permitted market entry. This case is currently under mediation.
  • In India, Novo Nordisk has partnered with Emcure Pharmaceuticals to distribute its drug under the brand name Poviztra, aiming for broader market reach.
  • The market is competitive, with Eli Lilly's tirzepatide (Mounjaro) rapidly gaining ground and even surpassing Wegovy in sales in India.
  • Novo Nordisk recently reduced Wegovy prices in India by 37% to combat competitive pressure.

Impact

  • This ruling could lead to increased competition and lower prices for semaglutide-based treatments, benefiting patients globally and in India.
  • It provides a significant opportunity for Dr Reddy's Laboratories and other Indian generic manufacturers to expand their global footprint in the lucrative obesity drug market.
  • Novo Nordisk may face increased competition and potential revenue erosion in markets where generic versions become available.
  • The decision reinforces the role of Indian pharmaceutical companies as key global suppliers of affordable generic medicines.
  • Impact rating: 8

Difficult Terms Explained

  • Semaglutide: A medication belonging to the GLP-1 receptor agonist class, primarily used to treat type-2 diabetes and promote weight loss.
  • Ozempic, Wegovy, Rybelsus: Brand names under which Novo Nordisk sells semaglutide. Ozempic and Wegovy are injectables, while Rybelsus is an oral form.
  • GLP-1 Receptor Agonist: A class of drugs that mimic the action of the naturally occurring hormone GLP-1, helping to regulate blood sugar and appetite.
  • Prima Facie: At first sight; based on initial examination. A legal finding that there is sufficient evidence to proceed with a case or grant a temporary order.
  • Patent Protection: Exclusive rights granted to an inventor for a limited period, preventing others from making, using, or selling the invention without permission.
  • Evergreening: A practice where a patent holder obtains new patents for minor modifications or new uses of an existing drug to extend its monopoly period beyond the original patent's expiry.
  • Bolar Exemption (Section 107A of the Patents Act): A legal provision that allows certain activities related to patented inventions for research or regulatory purposes, including the manufacture and export of drugs for non-commercial purposes or for markets where the patent is not in force.
  • Patent Infringement: The violation of a patent holder's exclusive rights by unauthorized making, using, selling, or importing of a patented invention.
  • Novelty: A requirement for an invention to be patentable; it must be new and not previously known or disclosed.
  • Single-judge bench: A court or a division of a court presided over by a single judge.
  • Division bench: A bench of two or more judges, typically an appellate court, hearing appeals from single-judge benches.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.